Table 1

Patient demographics and clinical characteristics at study entry

CharacteristicVitamin D groupPlacebo group
No of patients3432
Gender (F/M)21/1320/12
Age (years) (median, range)39 (22–53)35 (24–53)
BMI (kg/m2) (median, range)24 (18–40)24 (19–38)
EDSS score (median, range)2.0 (0–5.0)1.5 (0–4.0)
Disease duration (years) (median, range)3.0 (0.5–21.3)2.4 (0.2–15.2)
ARR (median, 95% CI)0.49 (0.31 to 0.66)0.52 (0.33 to 0.70)
Patients with relapses during the year preceding baseline (n (%))12 (35)13 (41)
Interferon therapy (years) (median, range)2.0 (0.2–12.4)1.4 (0.1–9.2)
Vitamin D intake (μg/day) (mean, range)2.1 (0–9.3)2.8 (0.3–7.9)
Calcium intake (mg/day) (mean, SD)1150 (502)1373 (495)
  • ARR, annual relapse rate from the 2 years before the study onset; BMI, body mass index; EDSS, Expanded Disability Status Scale.